Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047604 · ClinicalTrials.gov registry record · Phase 2
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02047604: Completed Phase 2 study, sponsored by Bausch Health Americas.
NCT02047604 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02047604, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Primary Outcome
Adverse events data are collected during a 10-week period, which includes 6 weeks of treatment and 4 weeks of follow-up.
Interventions
- DRUG SAN-300 0.5 mg/kg QW
- DRUG SAN-300 1.0 mg/kg QW
- DRUG SAN-300 2.0 mg/kg QOW
- DRUG SAN-300 4.0 mg/kg QOW
- DRUG SAN-300 4.0 mg/kg QW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-03-23 |
| Phase | Phase 2 |
What the finished NCT02047604 record still lists
NCT02047604 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 5 interventions - of which SAN-300 0.5 mg/kg QW is the first listed.
NCT02047604 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02047604 about?
NCT02047604 is a clinical study titled "(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis". A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
What is the current status of trial NCT02047604?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2013-12. Estimated completion is 2017-03-23.
What interventions are being tested in trial NCT02047604?
The interventions under investigation include: SAN-300 0.5 mg/kg QW (DRUG), SAN-300 1.0 mg/kg QW (DRUG), SAN-300 2.0 mg/kg QOW (DRUG), SAN-300 4.0 mg/kg QOW (DRUG), SAN-300 4.0 mg/kg QW (DRUG).
Who is sponsoring clinical trial NCT02047604?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02047604's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia